By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

Choose which cookies you allow
Necessary Required for the site to work, such as remembering this choice. Always active

AASLD Logo
IDSA Logo
Resource Library
  • Home
    • Table of Contents
    • Introductions
    • Methods
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
  • Test, Evaluate, Monitor
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
  • Treatment-Naive
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
    • Genotype 1
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
    • Genotype 2
      • GT2: No Cirrhosis
      • GT2: Compensated
    • Genotype 3
      • GT3: No Cirrhosis
      • GT3: Compensated
    • Genotype 4
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
  • Treatment-Experienced Patients
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
  • Unique & Key Populations
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
    • PWID, MSM & Corrections
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
  • About
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
AASLD Logo
IDSA Logo
    • Table of Contents
    • Introductions
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
      • GT2: No Cirrhosis
      • GT2: Compensated
      • GT3: No Cirrhosis
      • GT3: Compensated
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
Resource Library
  • Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009

    April 9, 2018
  • Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium

    August 30, 2017
  • Validation of a strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory

    May 3, 2017
  • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    May 3, 2017
  • Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study

    May 3, 2017
  • Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study

    May 3, 2017
  • ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection

    May 3, 2017
AASLD Logo
IDSA Logo
  • Test, Evaluate, Monitor
  • Treatment-Naive
  • Treatment-Experienced Patients
  • Key Populations With HCV Infection
  • Resource Library
  • About Us
  • Announcements
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Accessibility

© 2025 HCV Guidelines All right reserved.

Website by Yoko Co